The global rapid tests market size was estimated at USD 1.69 billion in 2025 and is projected to reach USD 3.25 billion by 2033, growing at a CAGR of 8.30% from 2026 to 2033. The growth can be attributed to the growing geriatric population, rising target disease burden, and increasing adoption of self-testing & point-of-care products.
Upper respiratory tract infections (URIs) remain extremely common worldwide, with incidence rates exceeding 162,000 per 100,000 people in recent global estimates, underscoring the need for rapid differentiation of viral versus bacterial causes in clinical practice.
Upper respiratory tract infections (URTIs) remain a major global health concern in 2025, with high incidence rates particularly in children under 5 and adults with underlying conditions. Children under 5 are the most affected group for URTIs, while 97% of pediatric RSV deaths occur in low- and middle-income countries.
Furthermore, Respiratory syncytial virus (RSV) is a highly prevalent viral infection that particularly affects infants, young children, and older adults. Globally, RSV is estimated to cause approximately 33 million acute lower respiratory tract infections annually in children under five years, with over 3 million cases requiring hospitalization. In the U.S., RSV leads to 58,000-80,000 hospitalizations and 100-300 deaths among children under five each year, as well as 60,000-160,000 hospitalizations and 6,000-10,000 deaths among adults aged 65 and older. Seasonal outbreaks typically occur in the fall and winter, significantly impacting healthcare systems and underscoring the critical need for effective diagnostic and preventive measures.
RSV rapid test demand is significant and growing, driven by pediatric and high-risk population screening.
hMPV contributes a smaller but meaningful share, especially where multiplex testing platforms incorporate hMPV targets.
Collectively, these drivers reflect how seasonal respiratory trends translate into diagnostic demand, highlighting the seasonality and pathogen-specific test utilization that underpins market expansion.
Across infectious disease surveillance and public health programs, rapid tests are increasingly playing a strategic role. Governments and health authorities in 2025 are scaling up access to rapid diagnostic kits for endemic conditions beyond COVID-19; for example, the Indian Council of Medical Research (ICMR) has advocated rapid test availability for conditions such as Hepatitis B, sickle cell anemia, and syphilis at primary health centres, aiming to improve early diagnosis in underserved areas. Meanwhile, markets for specific rapid tests, such as rapid influenza diagnostic tests (RIDTs), are projected to grow steadily as seasonal flu and respiratory illnesses persist globally. This widening scope of disease targets is expanding the application base of rapid diagnostics beyond upper respiratory infections and sepsis screening into the arenas of infectious and non-communicable diseases.
Innovation and competitive dynamics are reshaping the competitive landscape and product development trajectory. Providers are increasingly integrating advanced technologies such as AI, machine learning, and microfluidics to enhance test sensitivity, multiplexing, and ease of use, which supports broader adoption in both clinical and at-home settings. Established diagnostic players and new entrants are also influencing market growth paths: for instance, Amazon’s entry into home diagnostics services across major Indian cities in mid-2025 triggered notable shifts in investor sentiment in the diagnostics sector. At the same time, large strategic moves like Abbott’s planned acquisition of Exact Sciences - makers of widely used cancer and genetic tests signal diagnostic companies’ push to diversify beyond traditional rapid infectious disease testing into broader screening portfolios, even as they balance quality assurance and regulatory challenges in an increasingly crowded market.
Furthermore, the introduction of mobile applications, such as cobas infinity point-of-care from Roche Diagnostics, to satisfy the requirements of the POC coordinator and aid in enhancing productivity by completing the task on the smartphone irrespective of the destination, can be expected to drive the adoption of POC molecular diagnostic products during the forecast period.
Key players have shifted their focus to commercializing home-based self-testing products in recent years, and the COVID-19 outbreak has propelled this trend. Amid government-imposed lockdowns, such products addressed clinical needs while promoting self-quarantine practices. Companies, such as Abbott, have products like BinaxNOW Card rapid test for influenza and COVID-19 that delivers results at home in 15 minutes. This product comes with a virtual guide and application to enable the testing process and display test results.
Upper respiratory tract infections (URIs) remain extremely common worldwide, with incidence rates exceeding 162,000 per 100,000 people in recent global estimates, underscoring the need for rapid differentiation of viral versus bacterial causes in clinical practice.
Upper respiratory tract infections (URTIs) remain a major global health concern in 2025, with high incidence rates particularly in children under 5 and adults with underlying conditions. Children under 5 are the most affected group for URTIs, while 97% of pediatric RSV deaths occur in low- and middle-income countries.
Furthermore, Respiratory syncytial virus (RSV) is a highly prevalent viral infection that particularly affects infants, young children, and older adults. Globally, RSV is estimated to cause approximately 33 million acute lower respiratory tract infections annually in children under five years, with over 3 million cases requiring hospitalization. In the U.S., RSV leads to 58,000-80,000 hospitalizations and 100-300 deaths among children under five each year, as well as 60,000-160,000 hospitalizations and 6,000-10,000 deaths among adults aged 65 and older. Seasonal outbreaks typically occur in the fall and winter, significantly impacting healthcare systems and underscoring the critical need for effective diagnostic and preventive measures.
Below is a comparison of Virus detections by subtype reported to FluNet, 01 October 2017 to 30 December 2024, from countries in the Northern hemisphere, as of 07 January 2025:
The dataset plots estimated global volumes of rapid diagnostics that correspond with observed respiratory pathogen activity:
Influenza rapid test demand accounts for the largest share of total respiratory testing due to its high seasonal prevalence and broad availability of RIDTs. This results in high growth of the rapid influenza diagnostic tests market over the forecast years.RSV rapid test demand is significant and growing, driven by pediatric and high-risk population screening.
hMPV contributes a smaller but meaningful share, especially where multiplex testing platforms incorporate hMPV targets.
Collectively, these drivers reflect how seasonal respiratory trends translate into diagnostic demand, highlighting the seasonality and pathogen-specific test utilization that underpins market expansion.
Across infectious disease surveillance and public health programs, rapid tests are increasingly playing a strategic role. Governments and health authorities in 2025 are scaling up access to rapid diagnostic kits for endemic conditions beyond COVID-19; for example, the Indian Council of Medical Research (ICMR) has advocated rapid test availability for conditions such as Hepatitis B, sickle cell anemia, and syphilis at primary health centres, aiming to improve early diagnosis in underserved areas. Meanwhile, markets for specific rapid tests, such as rapid influenza diagnostic tests (RIDTs), are projected to grow steadily as seasonal flu and respiratory illnesses persist globally. This widening scope of disease targets is expanding the application base of rapid diagnostics beyond upper respiratory infections and sepsis screening into the arenas of infectious and non-communicable diseases.
Innovation and competitive dynamics are reshaping the competitive landscape and product development trajectory. Providers are increasingly integrating advanced technologies such as AI, machine learning, and microfluidics to enhance test sensitivity, multiplexing, and ease of use, which supports broader adoption in both clinical and at-home settings. Established diagnostic players and new entrants are also influencing market growth paths: for instance, Amazon’s entry into home diagnostics services across major Indian cities in mid-2025 triggered notable shifts in investor sentiment in the diagnostics sector. At the same time, large strategic moves like Abbott’s planned acquisition of Exact Sciences - makers of widely used cancer and genetic tests signal diagnostic companies’ push to diversify beyond traditional rapid infectious disease testing into broader screening portfolios, even as they balance quality assurance and regulatory challenges in an increasingly crowded market.
Furthermore, the introduction of mobile applications, such as cobas infinity point-of-care from Roche Diagnostics, to satisfy the requirements of the POC coordinator and aid in enhancing productivity by completing the task on the smartphone irrespective of the destination, can be expected to drive the adoption of POC molecular diagnostic products during the forecast period.
Key players have shifted their focus to commercializing home-based self-testing products in recent years, and the COVID-19 outbreak has propelled this trend. Amid government-imposed lockdowns, such products addressed clinical needs while promoting self-quarantine practices. Companies, such as Abbott, have products like BinaxNOW Card rapid test for influenza and COVID-19 that delivers results at home in 15 minutes. This product comes with a virtual guide and application to enable the testing process and display test results.
Global Rapid Tests Market Report Segmentation
This report forecasts revenue growth and provides an analysis on the latest trends in each of the sub-segments from 2021-2033. For this report, the analyst has segmented the global rapid tests market report based on the product, technology, application, end use, and region.Product Outlook (Revenue, USD Million, 2021-2033)
- Instruments
- Consumables
- Others
Technology Outlook (Revenue, USD Million, 2021-2033)
- Immunoassay
- Molecular Diagnostics
- Other technologies
Application Outlook (Revenue, USD Million, 2021-2033)
- Upper respiratory tract infections
- Antibiotic resistant infections
- Sepsis
End Use Outlook (Revenue, USD Million, 2021-2033)
- Hospitals & Clinics
- Laboratories
- At-home testing and Others
Regional Outlook (Revenue, USD Million, 2021-2033)
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East and Africa
Why You Should Buy This Report
- Comprehensive Market Analysis: Gain detailed insights into the market across major regions and segments.
- Competitive Landscape: Explore the market presence of key players.
- Future Trends: Discover the pivotal trends and drivers shaping the future of the market.
- Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.
This report addresses:
- Market intelligence to enable effective decision-making
- Market estimates and forecasts from 2018 to 2030
- Growth opportunities and trend analyses
- Segment and regional revenue forecasts for market assessment
- Competition strategy and market share analysis
- Product innovation listings for you to stay ahead of the curve
Table of Contents
Chapter 1. Methodology and Scope
Chapter 2. Executive Summary
Chapter 3. Market Variables, Trends, & Scope
Chapter 4. Technology Business Analysis
Chapter 5. Product Business Analysis
Chapter 6. Application Business Analysis
Chapter 7. End Use Business Analysis
Chapter 8. Regional Business Analysis
Chapter 9. Competitive Landscape
List of Tables
List of Figures
Companies Mentioned
The leading players profiled in this Rapid Tests market report include:- BD (Becton, Dickinson and Company)
- bioMérieux SA
- Thermo Fisher Scientific, Inc.
- F. Hoffmann-La Roche Ltd.
- Danaher Corporation
- DiaSorin S.P.A
- Abbott
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 130 |
| Published | February 2026 |
| Forecast Period | 2025 - 2033 |
| Estimated Market Value ( USD | $ 1.69 Billion |
| Forecasted Market Value ( USD | $ 3.25 Billion |
| Compound Annual Growth Rate | 8.3% |
| Regions Covered | Global |
| No. of Companies Mentioned | 8 |
